-
Signature
-
Robert Cloninger
-
Issuer symbol
-
WCN
-
Transactions as of
-
14 Feb 2022
-
Net transactions value
-
-$53,298
-
Form type
-
4
-
Filing time
-
16 Feb 2022, 16:04:02 UTC
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
WCN |
Common Shares |
Options Exercise |
$0 |
+513 |
+3.9% |
$0.000000 |
13,565 |
14 Feb 2022 |
Direct |
|
| transaction |
WCN |
Common Shares |
Tax liability |
$27,464 |
-230 |
-1.7% |
$119.41 |
13,335 |
14 Feb 2022 |
Direct |
F1 |
| transaction |
WCN |
Common Shares |
Options Exercise |
$0 |
+507 |
+3.8% |
$0.000000 |
13,842 |
15 Feb 2022 |
Direct |
|
| transaction |
WCN |
Common Shares |
Tax liability |
$25,834 |
-216 |
-1.6% |
$119.60 |
13,626 |
15 Feb 2022 |
Direct |
F1 |
| holding |
WCN |
Common Shares |
|
|
|
|
|
1,672 |
14 Feb 2022 |
Daughter |
|
| holding |
WCN |
Common Shares |
|
|
|
|
|
1,672 |
14 Feb 2022 |
Son |
|
| holding |
WCN |
Common Shares |
|
|
|
|
|
1,672 |
14 Feb 2022 |
Son |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
WCN |
Performance Share Units |
Options Exercise |
$0 |
-513 |
-33% |
$0.000000 |
1,025 |
14 Feb 2022 |
Common Shares |
513 |
$0.000000 |
Direct |
F2 |
| transaction |
WCN |
Performance Share Units |
Options Exercise |
$0 |
-507 |
-50% |
$0.000000 |
506 |
15 Feb 2022 |
Common Shares |
507 |
$0.000000 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
Remarks:
A performance share unit award was granted on February 15, 2019 and contained performance goals that the Issuer did not achieve over the three-year performance period from January 1, 2019 to December 31, 2021. The number of earned award units that vested at the end of the three-year performance period, as determined by the Compensation Committee of the Board of Directors, was 0% of the target number of shares subject to the award. No common shares were issued.